You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • SAT0249 Safety, pharmacokinetics, pharmacodynamics and inhibition of T-cell dependent antibody response (TDAR) with MEDI4920, a novel, engineered CD40 ligand (CD40L) antagonist: results of a first-time-in-human study

Article metrics

Article menu

Download PDFPDF

Poster Presentations
SLE, Sjögren's and APS - treatment
SAT0249 Safety, pharmacokinetics, pharmacodynamics and inhibition of T-cell dependent antibody response (TDAR) with MEDI4920, a novel, engineered CD40 ligand (CD40L) antagonist: results of a first-time-in-human study
Free

 

Online download statistics by month:

Online download statistics by month: June 2017 to August 2024

AbstractFullPdf
Jun 20171001
Jul 20176402
Aug 20179404
Sep 20175603
Oct 20174004
Nov 20174802
Dec 20177204
Jan 20186608
Feb 20189200
Mar 20186803
Apr 20186805
May 20189208
Jun 20185002
Jul 20188402
Aug 20187401
Sep 20182404
Oct 201880014
Nov 20184804
Dec 201852010
Jan 201996014
Feb 20196205
Mar 20195409
Apr 20194208
May 20194606
Jun 20192205
Jul 20193805
Aug 20193406
Sep 20192801
Oct 20191404
Nov 2019404
Dec 20191000
Jan 20202204
Feb 20203007
Mar 2020801
Apr 20201202
May 20201206
Jun 20203003
Jul 20201402
Aug 20201404
Sep 20203604
Oct 20203209
Nov 2020805
Dec 20202206
Jan 2021806
Feb 20211402
Mar 2021604
Apr 2021402
May 2021108
Jun 2021004
Jul 2021002
Aug 2021101
Sep 2021102
Oct 20215021
Nov 202118010
Dec 20211403
Jan 20221000
Feb 20223005
Mar 2022802
Apr 20221403
May 202228011
Jun 20224007
Jul 20223005
Aug 20222905
Sep 20223004
Oct 20222607
Nov 20221207
Dec 20221002
Jan 20233106
Feb 20232201
Mar 20231501
Apr 2023905
May 2023203
Jun 2023604
Jul 20231005
Aug 20231902
Sep 20231003
Oct 20231401
Nov 20232202
Dec 20232802
Jan 20242901
Feb 20241003
Mar 20248012
Apr 20242409
May 20244107
Jun 20241101
Jul 2024602
Aug 20244002
Total25680396